Research programme: targeted nanoparticle therapeutics - Pfizer

Drug Profile

Research programme: targeted nanoparticle therapeutics - Pfizer

Alternative Names: Accurins®; BIND 267; BIND-510; KSP inhibitor accurin; PLK1 inhibitor accurin; PSMA-targeted vincristine - Pfizer

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator BIND Biosciences
  • Developer BIND Therapeutics; Pfizer
  • Class
  • Mechanism of Action KIF11 protein inhibitors; Polo-like kinase 1 inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Haematological malignancies; Infections; Solid tumours
  • Discontinued Cardiovascular disorders; Inflammation

Most Recent Events

  • 21 Sep 2016 Affilogic and Takeda enter a research collaboration to develop targeted nanoparticle therapeutics
  • 05 May 2016 BIND Therapeutics and Affilogic enter a research collaboration to develop targeted nanoparticle therapeutics
  • 02 May 2016 BIND Therapeutics files for Chapter 11 bankruptcy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top